Johnson & Johnson

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, LLY has a market cap of 929.6B. Regarding current trading prices, JNJ is priced at $243.07, while LLY trades at $985.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas LLY's P/E ratio is 42.84. In terms of profitability, JNJ's ROE is +0.34%, compared to LLY's ROE of +0.98%. Regarding short-term risk, JNJ is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check LLY's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, ABBV has a market cap of 388.4B. Regarding current trading prices, JNJ is priced at $243.07, while ABBV trades at $221.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas ABBV's P/E ratio is 92.70. In terms of profitability, JNJ's ROE is +0.34%, compared to ABBV's ROE of -3.62%. Regarding short-term risk, JNJ is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check ABBV's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, NVS has a market cap of 296.7B. Regarding current trading prices, JNJ is priced at $243.07, while NVS trades at $154.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas NVS's P/E ratio is 21.47. In terms of profitability, JNJ's ROE is +0.34%, compared to NVS's ROE of +0.33%. Regarding short-term risk, JNJ is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for JNJ.Check NVS's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, AZN has a market cap of 294.4B. Regarding current trading prices, JNJ is priced at $243.07, while AZN trades at $191.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas AZN's P/E ratio is 29.08. In terms of profitability, JNJ's ROE is +0.34%, compared to AZN's ROE of +0.23%. Regarding short-term risk, JNJ is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for JNJ.Check AZN's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, MRK has a market cap of 285.8B. Regarding current trading prices, JNJ is priced at $243.07, while MRK trades at $115.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas MRK's P/E ratio is 15.90. In terms of profitability, JNJ's ROE is +0.34%, compared to MRK's ROE of +0.36%. Regarding short-term risk, JNJ is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check MRK's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, AMGN has a market cap of 197.4B. Regarding current trading prices, JNJ is priced at $243.07, while AMGN trades at $368.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas AMGN's P/E ratio is 25.72. In terms of profitability, JNJ's ROE is +0.34%, compared to AMGN's ROE of +0.97%. Regarding short-term risk, JNJ is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check AMGN's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, GILD has a market cap of 180B. Regarding current trading prices, JNJ is priced at $243.07, while GILD trades at $145.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas GILD's P/E ratio is 17.79. In terms of profitability, JNJ's ROE is +0.34%, compared to GILD's ROE of +0.41%. Regarding short-term risk, JNJ is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check GILD's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, NVO has a market cap of 168.7B. Regarding current trading prices, JNJ is priced at $243.07, while NVO trades at $38.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas NVO's P/E ratio is 10.61. In terms of profitability, JNJ's ROE is +0.34%, compared to NVO's ROE of +0.61%. Regarding short-term risk, JNJ is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check NVO's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, PFE has a market cap of 151.2B. Regarding current trading prices, JNJ is priced at $243.07, while PFE trades at $26.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas PFE's P/E ratio is 19.41. In terms of profitability, JNJ's ROE is +0.34%, compared to PFE's ROE of +0.09%. Regarding short-term risk, JNJ is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for JNJ.Check PFE's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, BMY has a market cap of 120.3B. Regarding current trading prices, JNJ is priced at $243.07, while BMY trades at $59.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas BMY's P/E ratio is 17.07. In terms of profitability, JNJ's ROE is +0.34%, compared to BMY's ROE of +0.39%. Regarding short-term risk, JNJ is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for JNJ.Check BMY's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, GSK has a market cap of 107B. Regarding current trading prices, JNJ is priced at $243.07, while GSK trades at $54.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas GSK's P/E ratio is 14.31. In terms of profitability, JNJ's ROE is +0.34%, compared to GSK's ROE of +0.30%. Regarding short-term risk, JNJ is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for JNJ.Check GSK's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, SNY has a market cap of 105.3B. Regarding current trading prices, JNJ is priced at $243.07, while SNY trades at $43.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas SNY's P/E ratio is 18.63. In terms of profitability, JNJ's ROE is +0.34%, compared to SNY's ROE of +0.11%. Regarding short-term risk, JNJ is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for JNJ.Check SNY's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, BIIB has a market cap of 26.6B. Regarding current trading prices, JNJ is priced at $243.07, while BIIB trades at $183.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas BIIB's P/E ratio is 20.40. In terms of profitability, JNJ's ROE is +0.34%, compared to BIIB's ROE of +0.07%. Regarding short-term risk, JNJ is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check BIIB's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, JNJ is priced at $243.07, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas HZNP's P/E ratio is 61.86. In terms of profitability, JNJ's ROE is +0.34%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, JNJ is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for JNJ.Check HZNP's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, GRFS has a market cap of 6.6B. Regarding current trading prices, JNJ is priced at $243.07, while GRFS trades at $7.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas GRFS's P/E ratio is 12.20. In terms of profitability, JNJ's ROE is +0.34%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, JNJ is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for JNJ.Check GRFS's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, OGN has a market cap of 1.7B. Regarding current trading prices, JNJ is priced at $243.07, while OGN trades at $6.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas OGN's P/E ratio is 8.96. In terms of profitability, JNJ's ROE is +0.34%, compared to OGN's ROE of +0.26%. Regarding short-term risk, JNJ is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check OGN's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, CELG-RI has a market cap of 268M. Regarding current trading prices, JNJ is priced at $243.07, while CELG-RI trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, JNJ's ROE is +0.34%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, JNJ is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check CELG-RI's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, CTOR has a market cap of 71.7M. Regarding current trading prices, JNJ is priced at $243.07, while CTOR trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas CTOR's P/E ratio is -2.62. In terms of profitability, JNJ's ROE is +0.34%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, JNJ is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check CTOR's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, SCLX has a market cap of 70.7M. Regarding current trading prices, JNJ is priced at $243.07, while SCLX trades at $8.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas SCLX's P/E ratio is -0.20. In terms of profitability, JNJ's ROE is +0.34%, compared to SCLX's ROE of +1.81%. Regarding short-term risk, JNJ is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check SCLX's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, MIRA has a market cap of 50.7M. Regarding current trading prices, JNJ is priced at $243.07, while MIRA trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas MIRA's P/E ratio is -0.76. In terms of profitability, JNJ's ROE is +0.34%, compared to MIRA's ROE of -9.79%. Regarding short-term risk, JNJ is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check MIRA's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, SRXH has a market cap of 4.8M. Regarding current trading prices, JNJ is priced at $243.07, while SRXH trades at $0.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas SRXH's P/E ratio is -0.83. In terms of profitability, JNJ's ROE is +0.34%, compared to SRXH's ROE of +4.36%. Regarding short-term risk, JNJ is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check SRXH's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, SCLXW has a market cap of 1.2M. Regarding current trading prices, JNJ is priced at $243.07, while SCLXW trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas SCLXW's P/E ratio is N/A. In terms of profitability, JNJ's ROE is +0.34%, compared to SCLXW's ROE of +1.81%. Regarding short-term risk, JNJ is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for JNJ.Check SCLXW's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, JNJ is priced at $243.07, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas BDSIW's P/E ratio is N/A. In terms of profitability, JNJ's ROE is +0.34%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, JNJ is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check BDSIW's competition here

JNJ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 582.1B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, JNJ is priced at $243.07, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 21.88, whereas CRXT's P/E ratio is -0.02. In terms of profitability, JNJ's ROE is +0.34%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, JNJ is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for JNJ.Check CRXT's competition here